Cite
HARVARD Citation
Dorff, T. et al. (n.d.). 340 Phase 1 study of AMG 160, a half-life extended BiTE® (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer. Journal for immunotherapy of cancer. pp. A207-A208. [Online].